TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in Cancers detailing preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study revealed that TTX-MC138 accumulated in metastatic bone lesions after systemic administration, reduced expression of microRNA-10b (miR-10b), and increased expression of the downstream tumor-suppressor target HOXD10, leading to significant survival benefits compared with controls. Repeated dosing was well tolerated, with no observed systemic toxicity.
These findings further validate TransCode's innovative approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology. The results also suggest potential applicability across additional metastatic disease settings, which could broaden the therapeutic impact of TTX-MC138 beyond breast cancer bone metastasis. According to the company, miR-10b is a well-documented biomarker of metastasis, overexpressed in various aggressive tumors, making it an attractive target for therapeutic intervention.
The study's outcomes are particularly noteworthy because bone metastasis is a common and debilitating complication in advanced breast cancer, often leading to skeletal-related events and poor prognosis. By demonstrating that TTX-MC138 can effectively target metastatic lesions and improve survival in a preclinical model, TransCode provides a strong rationale for advancing this candidate into further clinical development.
TransCode Therapeutics is dedicated to pioneering treatments for high-risk and advanced cancers. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. This latest publication reinforces the potential of RNA-based therapeutics in oncology and highlights the importance of targeting metastatic processes.
The full press release can be accessed at https://ibn.fm/E6gbq. For more information about TransCode Therapeutics, visit their newsroom at https://ibn.fm/RNAZ.
